Prof. Ioannis Zervantonakis' research integrates microfluidics, systems biology, and in vivo models to study cancer metastasis, drug resistance, and tumor microenvironment interactions in cancers. His lab develops synthetic biology tools such as microfluidic assays to model tumor-immune interactions, investigates single-cell phenotypic decisions, and explores localized drug delivery strategies. Their long-term goal is to identify biomarkers for improved therapies and personalized cancer treatments.
"A large peptidome dataset improves HLA class I epitope prediction across most of the human population"
Sarkizova S, Klaeger S, Le PM, Li LW, Oliveira G, Keshishian H, Hartigan CR, Zhang W, Braun DA, Ligon KL, Bachireddy P, Zervantonakis IK, Rosenbluth JM, Ouspenskaia T, Law T, Justesen S, Stevens J, Lane WJ, Eisenhaure T, Lan Zhang G, Clauser KR, Hacohen N, Carr SA, Wu CJ, Keskin DB. Nat Biotechnol. 2020, 38, 2, 199-209
"Beyond matrix stiffness: targeting force-induced cancer drug resistance"
Kalli M, Poskus MD, Stylianopoulos T, Zervantonakis IK. Trends Cancer. 2023, 9, 11, 937-954
"Therapy resistance: opportunities created by adaptive responses to targeted therapies in cancer"
Labrie M, Brugge JS, Mills GB, Zervantonakis IK. Nat Rev Cancer. 2022, 26, 6, 323-339
"Multiomics identifies tumor-intrinsic SREBP1 driving immune exclusion in hepatocellular carcinoma"
Dadey RE, Li R, Griner J, Chen J, Singh A, Isett B, Newman S, Augustin R, Li A, Manning JA, Monga SP, Singhi A, Geller DAA, Krieg C, Zervantonakis IK, Luke JJ, Bao R. J Immunother Cancer. 2025, 13, 6, e011537
"Cancer-mesothelial and cancer-macrophage interactions in the ovarian cancer microenvironment"
Jazwinska DE, Kulawiec DG, Zervantonakis IK. Am J Physiol Cell Physiol. 2023, 325, 3, C721-C730